82 results about "Hemofiltration" patented technology

A system, method and apparatus for performing a renal replacement therapy is provided. In one embodiment, two small high flux dialyzers are connected in series. A restriction is placed between the two dialyzers in the dialysate flow path. The restriction is variable and adjustable in one preferred embodiment. The restriction builds a positive pressure in the venous dialyzer, causing a high degree of intentional backfiltration. That backfiltration causes a significant flow of dialysate through the high flux venous membrane directly into the patient's blood. That backfiltered solution is subsequently ultrafiltered from the patient from the arterial dialyzer. The diffusion of dialysate into the venous filter and removal of dialysate from the arterial dialyzer causes a convective transport of toxins from the patient. Additionally, the dialysate that does not diffuse directly into the patient but instead flows across the membranes of both dialyzers provides a diffusive clearance of waste products.

In a blood dialysis system including a source of substitution fluid (10) and a blood dialysis machine, a hemodiafiltration system having a first dialyzer (1) including a first blood compartment (4) having a first blood inlet which receives blood to be cleaned and a first blood outlet which discharges partially diafiltered blood and a first dialysate compartment (5) having a first dialysate inlet and a first dialysate outlet, means (8) for mixing the partially diafiltered blood with substitution fluid from the source to obtain a blood / substitution fluid mixture, and a second hemofilter (2) including a second blood compartment (11) having a second blood inlet which receives the blood / substitution fluid mixture and a second blood outlet which discharges filtered blood and a second permeate compartment (12) having a second permeate outlet.

A flow loop for hemodialysis, hemodiafiltration and hemofiltration for the treatment of pathological conditions such as End Stage Renal Disease (ESRD) that has a controlled compliant flow path for preparing fluids required for a hemodialysis therapy session from water. The controlled compliant flow path modifies water into any one of a solution for priming a hemodialysis system, a physiologically compatible solution for contacting blood, a physiologically compatible solution for infusion to a subject, and a solution for blood rinse back to a subject. The controlled compliant flow path has a means for selectively metering in and metering out fluid from the flow path.

Systems and methods for using a sodium chloride source and a buffer source such as sodium bicarbonate in a controlled compliant flow path to generate from water a physiologically compatible fluid having a suitable level of a sodium ion and / or a buffer for use in hemodialysis, hemodiafiltration and hemofiltration. The system has a conditioning flow path that has at least a salination valve or salination pump, and at least one container has at least one solute in excess of the solubility of that solute. At least one of the solutes is a buffer source or sodium chloride. The conditioning flow path is in fluid communication with a controlled compliant flow path. The conditioning flow path can selectively meter fluid into and out of the controlled compliant flow path.

A degassing module for removal of air and other gases during operation of a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The degassing module has a flow-through first chamber that has a hydrophobic vent membrane that has an exterior and interior side forming a portion of the flow-through chamber. The hydrophobic vent membrane is positioned at a higher elevation on the flow-through chamber than a fluid outlet. Fluid flows through the flow-through chamber in a downward direction relative to the hydrophobic vent membrane. A flow-through chamber has a cross sectional area configured to provide for a downward flow velocity of the fluid to be less than the upward rise velocity of a smallest bubble to be removed from the fluid.

Systems and methods for cleaning and disinfecting a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The system has a base module that has at least one segment of a controlled compliant flow path and at least one pair of jumpered ports configured on the base module. One or more components have connections connectable to the jumpered ports of the base module to provide for fluid communication between the segment of the controlled compliant flow path in the base module and a flow path defined by the one or more components. The base module is connected to the one or more components that define a flow path configurable for carrying out in part at least one function performed during any one of hemodialysis, hemodiafiltration or hemofiltration.

Method and device for monitoring the flow speed of an infusion solution, such as with hemofiltration or hemodiafiltration. The device has a tube for conducting an infusion solution from a source of infusion solution to a pump device in the form of a metering pump, such as a peristaltic pump or a ceramic pump, and on to an infusion device, such as a drip chamber. The flow speed is determined by the metering pump. The flow speed is monitored separately in that the pressure across a restriction device in the tube is measured. The restriction device can be a separately arranged restriction valve. Alternatively the restriction device is arranged by the tube having a small internal diameter of the order of 0.5 mm in size. The pressure measuring device only needs to measure the absolute pressure with respect to the atmosphere. The hydrostatic pressure due to the infusion bag being hung above the pump and the pressure meter is subtracted in a calculation device.

A method for making a polysulfone having zwitterionic functionality comprising reacting a piperazine amine functionalized polysulfone with sultone is described as are blends with other polymers. Membranes containing polysulfones having zwitterionic functionality are also provided. Membranes thus formed are used in hemodialysis, hemofiltration, and water purification.

A degassing module for removal of air and other gases during operation of a medical therapy device that delivers any one of hemodialysis, hemodiafiltration and hemofiltration. The degassing module has a flow-through first chamber that has a hydrophobic vent membrane that has an exterior and interior side forming a portion of the flow-through chamber. The hydrophobic vent membrane is positioned at a higher elevation on the flow-through chamber than a fluid outlet. Fluid flows through the flow-through chamber in a downward direction relative to the hydrophobic vent membrane. A flow-through chamber has a cross sectional area configured to provide for a downward flow velocity of the fluid to be less than the upward rise velocity of a smallest bubble to be removed from the fluid.

Permselective asymmetric membranes suitable e.g. for hemodialysis, hemodiafiltration and hemofiltration of blood, and having improved sieving characteristics providing enhanced removal of middle molecular weight substances, e.g. inflammatory mediators having a molecular weight between 20 and 40 kDa. The membranes comprise polyethersulfone and polyvinylpyrrolidone and are coated with hyaluronic acid or copolymers of 2-methacryloyloxyethyl phosphoryl choline and other vinyl polymerizable monomers. Processes for the preparation of these membranes, devices comprising these membranes, and the use of these membranes in hemodialysis, hemodiafiltration and hemofiltration of blood, as well as in bioprocessing, plasma fractionation and the preparation of protein solutions.

The present invention relates to systems, methods and uses for recycling at least a part of water lost during various renal replacement therapy processes, e.g. in the preparation of a fresh dialysate solution or fresh reconstitution fluid for kidney disease dialysis and hemofiltration by utilizing water from the spent fluids. The system of the invention is useful in hemodialysis and in peritoneal dialysis as well as in hemofiltration for reuse of water from filtrates and spent fluids. In addition, the system of the invention is useful in the development of a renal assist device or artificial kidney.

The invention relates to extracorporeal blood circuits, and components thereof (e. g. , hollow fiber membranes, potted bundles, and blood tubing), including 0. 005% to 10% (w / w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.

There is provided a method of reducing blood free light chain concentration in a subject, the method comprising the step of subjecting the subject's blood to haemodialysis, haemodiafiltration or haemofiltration. There is also provided the use of a dialysis membrane which is a membrane that allows passage of molecules having a molecular weight of up to 45 kDa in presence of whole blood, and has a molecular weight exclusion limit in water of about 200 kDa in the preparation of a haemodialysis unit for conducting haemodialysis, haemodiafiltration or haemofiltration on a subject to reduce blood free light chain concentration in the patient.

The invention relates to an adsorbent used for clearing middle and macro molecule toxin in body of uremia patients and a preparation method thereof. According to the molecule size of middle and macromolecules such as beta2-MG, PTH, AGEs, Hcy and IL-6 and performance characteristics thereof, a functional adsorbent which can efficiently clear main middle and macro molecule toxins such as beta2-MG,PTH, AGEs, Hcy and IL-6 in the blood of the uremia patients is prepared by taking a mesoporous polystyrene hydrophobic resin as a carrier, which undergoes chloromethylation activation, and then performing chemical crosslinking grafting of vinylamine; and the adsorbent has large adsorption capacity, good mechanical strength, good biocompatibility and high adsorption selectivity. The adsorbent is used for treating uremia by blood perfusion, can take the advantages of blood filtering mainly for clearing micromolecular toxin, and provides a new method for treating uremia by combination of hematodialysis and blood perfusion.

Membranes for use in methods and apparatuses for hemodialysis and hemofiltration are composed of at least one polyarylethernitrile block copolymer having structural units of formula IwhereinZ is a direct bond, O, S, CH2, SO, SO2, CO, RPO, CH2, alkenyl, alkynyl, a C1-C12aliphatic radical, a C3-C12cycloaliphatic radical, a C3-C12aromatic radical or a combination thereof;R is a C6-12 aromatic radical or a C1-12aliphatic radical;R1 and R2 are independently H, halo, nitro, a C1-C12aliphatic radical, a C3-C12cycloaliphatic radical, a C3-C12aromatic radical, or a combination thereof;a is 0, 1, 2 or 3;b is 0, 1, 2, 3 or 4; andm and n are independently 0 or 1.

The invention discloses an extracorporeal circulation life supporting device used for treating and curing multiple organ failure. The extracorporeal circulation life supporting device comprises an extracorporeal circulation pipeline which is connected between a vein or artery outlet end of a patient and a vein blood inlet end of the patient; a heparin pump, a first blood pump and a second blood pump are arranged on the extracorporeal circulation pipeline in turn; the extracorporeal circulation pipeline is branched into a first branch and a second branch between the first blood pump and the second blood pump; an oxygen combiner is arranged on the first branch; the second branch extends from the second blood pump which is provided with a blood clamp, a plasma separator, an active carbon jar and a resin jar are arranged at the lower edge of the second blood pump; the plasma outputted from a side wall of the plasma separator enters into the active carbon jar and the resin jar and enters into a blood filter together with the blood cells outputted from an outlet end of the plasma separator; the blood is purified and is applied to a supporting device for curing renal failure; all the branches are converged and enter into the body of the patient from the vein end. According to the extracorporeal circulation life supporting device, one device is used for independently or jointly supporting / replacing the heart, lung, liver and renal function failure.

The invention relates to a formula of a blood filtration replacement fluid which is special for citrate anticoagulation, a preparation method and a usage thereof. With the components of sodium citrate, sodium chloride, potassium chloride, sodium lactate, citric acid and so on, the replacement fluid is mainly used for blood filtration and blood dialysis filtration of the patients with acute renal failure or high risk bleeding due to multiple organ failure etc., and can solve the problems of easy occurrence of hypernatremia and alkali poisoning in the prior citrate anticoagulation, thus facilitating the clinical usage. The replacement fluid has the advantages of strong applicability, exact efficacy and low toxicity and side effects; the preparation process is simple; the quality is stable, safe and effective; the feasibility is strong; the repeatability is high; and the replacement fluid is applicable to the large-scale production and the promotion of the clinical application, thus being the ideal blood filtration replacement fluid for blood filtration, blood dialysis filtration, continuous renal replacement therapy and so on. The demand of the blood dialysis increases along with the increasing number of the patients with the end-stage renal failure year by year, so the blood filtration replacement fluid can generate more tremendous economic and social benefits.

A method for hemodialysis and hemofiltration includes contacting blood with a porous membrane in a hollow fiber or flat sheet configuration. The membrane comprises a polyarylethernitrile sulfone having structural units of formula IwhereinR1 and R2 are independently H, nitro, a C1-C12 aliphatic radical, a C3-C12 aromatic radical, or a combination thereof;a is 0, 1, 2 or 3;b is 0, 1, 2, 3 or 4; andm and n are independently 0 or 1.

A method for making a polysulfone having zwitterionic functionality comprising reacting a piperazine amine functionalized polysulfone with sultone is described as are blends with other polymers. Membranes containing polysulfones having zwitterionic functionality are also provided. Membranes thus formed are used in hemodialysis, hemofiltration, and water purification.

The invention discloses an immunochromatography test strip for detecting cystic echinococcosis and a preparation method thereof. The test strip comprises a hemofiltration membrane sample pad, a gold-marking pad, a cellulose membrane and a water absorption pad, wherein the gold-marking pad is tightly connected with the hemofiltration membrane sample pad and comprises an antibody labeling colloid gold probe of anti-echinococcus antigen advantage special antibody subtypes, the cellulose membrane is tightly connected with the gold-marking pad, the water absorption pad is tightly connected with the other end of the cellulose membrane, a detection line and a quality control line are arranged on the cellulose membrane, the detection line comprises crude antigens aiming at the cystic echinococcosis, and the quality control line comprises anti-antibodies capable of realizing special combination with the antibodies of the anti-echinococcus antigen advantage special antibody subtypes. The immunochromatography test strip of the invention has the advantages of simplicity, convenience, sensitivity, specificity and high speed, and is applicable to clinical and field use.

A Continuous Ambulatory Hemofilter includes an outer casing, multifunction pump, hemofilter, reverse osmosis filter, power source, drainage bag, blood lines and fluid lines, characterized in that the hemofiltrate from the hemofilter is moved to a reverse osmosis filter. The ultrafiltrate fluid from the reverse osmosis filter flows to the out-flow tube of the hemofilter vein line through a dedicated fluid line. The exit of the reverse osmosis filter is connected to a drainage bag. The multifunction pump moves blood from a permanent jugular catheter to the hemofilter, and fluids between the hemofilter, reverse osmosis filter, vein line and drainage bag. An electrode is placed at the in-flow tube of the hemofilter to measure incoming blood osmolality. The electrode is connected to a microprocessor that is further connected to a computer-controlled valve at the out-flow line of the reverse osmosis filter. The microprocessor is connected with a memory card.

The general disclosure discusses a system and method for improving the efficacy of blood filtration treatments such as hemodialysis, hemofiltration, and hemodiafiltration. More particularly, the disclosure discusses a microfluidic device that includes first and second channels separated by a permeable membrane. One of the channels is configured for blood flow and includes a protein gel disruption layer. The protein gel disruption layer includes a plurality of elements at least partially extending across the blood flow channel that reduce the formation of a boundary layer or gel layer at the blood-membrane interface.

The invention belongs to the field of leukocyte filters, and particularly relates to a leukocyte and thrombocyte filtering membrane and a preparation method thereof. The filtering membrane comprises a composite substrate and a polymer applied to the composite substrate, wherein the composite substrate is prepared from polyurethane and nano-microcrystalline cellulose according to the weight ratio of 1:(0.3-2), and the polymer is prepared from polyethylene glycol and nano-hydroxyapatite according to the weight ratio of 10:(1-2). According to the filtering membrane, leukocytes and thrombocytes can be efficiently filtered while the blood filtering speed is not decreased, the highest filtering rate of the leukocytes and the highest filtering rate of the thrombocytes can reach 99.999% and 92.4% respectively, and only 15-20 min is needed for filtering 400 ml of whole blood; meanwhile, the filtering membrane has the good flexibility, meets the requirement that moderate deformation is needed when the filtering membrane is packaged and can effectively solve the problem that the polymer is prone to be washed out in the subsequent washing process.

The invention discloses a blood purifier. The blood purifier comprises an artery pipe, a vein pipe and a blood filter. The artery pipe communicates with an artery kettle after bypassing a blood pump, and the vein pipe communicates with a vein kettle. A displacement liquid communicates with the vein kettle after bypassing a displacement liquid pump through pipes. A liquid waste output port of the blood filter communicates with a liquid waste collecting bag after bypassing a liquid waste pump through pipes. One in-film joint of the blood filter communicates with a first multi-pipe gating switch, and the other in-film joint of the blood filter communicates with a second multi-pipe gating switch. The first multi-pipe gating switch communicates with the vein kettle, and the second multi-pipe gating switch communicates with the artery kettle. Both the first multi-pipe gating switch and the second multi-pipe gating switch have ports connected with a blood filter to be replaced. The blood purifier can solve the problems, such as blood exosmosis, increase of financial burden for a patient caused by frequently whole pipe replacement, influence on blood filtration, and increase of risk of blood infection, caused by direct separation of cruor in pipes during blood purification and installation of pipes and a blood filter.

The invention relates to a hemofiltration or hemodialysis solution. The compositions of the hemofiltration or hemodialysis solution are sodium salt or sodium salt hydrate, magnesium salt or magnesium salt hydrate, calcium salt or calcium salt hydrate and organic acid salt or organic acid salt hydrate, wherein the arithmetic product (Ksp) of the solubility of organic acid ions and calcium ions is more than 6X10<-9>(25 DEG C). The invention also provides a medicinal product, which comprises at least two compartments or independent packages; and the compositions of the hemofiltration or hemodialysis solution are respectively arranged in the compartments or the packages by means of different combinations, wherein the compartments contain the calcium salt or the packages do not contain carbonate.

Methods, systems, and kits are provided for performing hemodialysis, hemodiafiltration, and peritoneal dialysis on a portable machine suitable for both clinical and home use. Peritoneal dialysate can be flowed into and out of the peritoneal cavity, and can also be regenerated within the system, without the need for introducing fresh dialysate. Common hardware and software can be utilized for both peritoneal dialysis and other forms of dialysis such as hemodialysis, hemofiltration, and hemodiafiltration, allowing for facile transition between different dialysis modes using the same dialysis machine.